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Huntington’s disease cerebrospinal ﬂuid seeds aggregation of
mutant huntingtin
Z Tan1, W Dai2, TGM van Erp3, J Overman4, A Demuro4, MA Digman5, A Hatami6,12, R Albay6, EM Sontag4,13, KT Potkin3, S Ling3,
F Macciardi3, WE Bunney3, JD Long7,8, JS Paulsen7,9, JM Ringman10, I Parker4, C Glabe1,6,11, LM Thompson1,3,4, W Chiu2 and SG Potkin3
Huntington’s disease (HD), a progressive neurodegenerative disease, is caused by an expanded CAG triplet repeat producing a
mutant huntingtin protein (mHTT) with a polyglutamine-repeat expansion. Onset of symptoms in mutant huntingtin gene-carrying
individuals remains unpredictable. We report that synthetic polyglutamine oligomers and cerebrospinal ﬂuid (CSF) from BACHD
transgenic rats and from human HD subjects can seed mutant huntingtin aggregation in a cell model and its cell lysate. Our studies
demonstrate that seeding requires the mutant huntingtin template and may reﬂect an underlying prion-like protein propagation
mechanism. Light and cryo-electron microscopy show that synthetic seeds nucleate and enhance mutant huntingtin aggregation.
This seeding assay distinguishes HD subjects from healthy and non-HD dementia controls without overlap (blinded samples).
Ultimately, this seeding property in HD patient CSF may form the basis of a molecular biomarker assay to monitor HD and evaluate
therapies that target mHTT.
Molecular Psychiatry (2015) 20, 1286–1293; doi:10.1038/mp.2015.81; published online 23 June 2015
INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neurodegen-
erative disease that results in progressive motor, cognitive and
psychiatric impairment and ultimately death. The disease is caused
by an abnormal CAG trinucleotide repeat expansion within exon 1
of the HD gene that produces a mutant huntingtin protein (mHTT)
containing an expanded polyglutamine (poly(Q)n, n⩾ 36) tract.1
The length of the expansion has an inverse relationship to the age-
of-onset of clinical motor symptoms.2,3 The repeat expansion
confers an increased misfolding and aggregation propensity to
mHTT, leading to the build-up of soluble and insoluble mHTT
aggregates and a corresponding deﬁcit in the intracellular quality
control of protein folding.4–6 Amino terminal fragments of
expanded polyQ-containing mHTT protein can readily form
oligomers and ultimately insoluble beta-sheet-rich amyloid-like
ﬁbrillar aggregates in vitro and in vivo in a polyQ length-dependent
manner.7 The ultimate relationship of speciﬁc aggregation species
to disease manifestation is unclear. Although the inability to clear
mHTT may represent a major pathogenic property,8 the propensity
to aggregate represents a property of mHTT that reproducibly
correlates with disease pathogenesis.9
A potentially central concept has emerged recently for
neurodegenerative diseases including Alzheimer’s, Parkinson’s
and HD that transcellular protein aggregation and propagation
may occur and reﬂect an underlying and associated spreading of
misfolded mutant proteins.9 On the basis of previous studies
demonstrating that intracellular aggregation of mHTT can be
‘seeded‘ by addition of exogenous polyglutamine peptides,10,11
we report here that cerebrospinal ﬂuid (CSF) from a rat model of
disease and from human HD subjects contains a mHTT-dependent
property that seeds aggregation. To evaluate this property, we
developed a quantitative cell-based aggregation (CBA) seeding
assay. This seeding assay has two measures—the percentage of
cells with aggregates12 and the amount of aggregates in cell
lysates. The lysates are obtained from Htt14A2.6 PC12 cells that
inducibly express expanded repeat mHTT polypeptide. We
demonstrate that seeding is dose dependent and that extra-
cellular seeds are incorporated into endogenously expressed
mHTT species, forming aggregated ﬁbrils. Seeding can be
immunodepleted with antibody to mHTT, demonstrating that
the CBA assay is mHTT dependent. This incorporation was
visualized in cell extracts by correlative cryogenic-ﬂuorescent light
microscopy (cryo-FLM) and cryo-electron tomography (cryo-ET).
Using the CBA assay as a measure of pathophysiological changes
in HD, CSF from an HD rat model and human HD patients was
found to ‘seed‘ signiﬁcantly more aggregates compared with
CSF from non-HD subjects. Mutant HTT can be detected in CSF
from both HD autopsy samples and living HD subjects on
ﬁlter blots with antibodies, and in the CBA seeding assay.
These ﬁndings support transcellular propagation and associated
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spreading of misfolded mHTT protein and raise the possibility of using
this seeding as a sensitive molecular biomarker assay to assess mHTT
levels and aggregation propensity in HD. No effective disease-
modifying treatments are currently available for HD. The lack of
predictive and efﬁcient blood or CSF biomarkers that track with
clinical, neuropathological and molecular measures of disease
progression has been a critical barrier to the development of effective
HD treatments. The ﬁndings presented raise the possibility of using
the seeding property inherent in HD CSF as a molecular biomarker
assay to assess mHTT levels and aggregation propensity in HD.
MATERIALS AND METHODS
Oligomeric seeds
PolyQ seeds were prepared from synthetic peptides of polyQ30 and
polyQ40 as described previously.13 The preparation of Alexa Fluor 647-,
Cy3-labeled polyQ40 seeds and HiLyte Fluor 647-labeled Aβ1–40 and Aβ1–42
are described in the Supplementary Materials.
CSF samples
Investigators were blinded to sample group membership and speciﬁc
diagnoses. Postmortem CSF was obtained from the UCLA Human Brain
and Spinal Fluid Resource Center. The number of CAG repeats for HD cases
were genotyped by Laragen (Culver City, CA, USA) using dissected frozen
brain tissues. The dementia control CSF was provided by the Easton Center
for Alzheimer’s Disease Research at UCLA. PREDICT CSF samples were
provided by Coriell Institute for Medical Research. BACHD rat samples were
provided by CHDI Foundation. CSF was aspirated from BACHD rats as
described in the Supplementary Materials. For the immunodepletion of
mHTT in CSF experiment, 100 μl CSF was incubated with 20 μl protein A/G
PLUS-Agrose beads (Santa Cruz Biotechnologies, Dallas, TX, USA) that were
preconjugated with varying amount of MAB1574 polyQ expansion-speciﬁc
antibody (EMD Millipore, Temecula, CA, USA) for 1 h at 4 °C with gentle
mixing. The supernatants were saved for aggregation seeding assays.
Cell culture and cell-based seeding assay
The Htt14A2.6 PC12 line was generated and propagated as described
previously.12 In brief, Htt14A2.6 was maintained in Dulbecco's modiﬁed eagle
medium-GlutaMAX (Life Technologies, Grand Island, NY, USA) supplemented
with horse serum (10%), heat-inactivated fetal bovine serum (5%), Pen Strip
(1%), Zeocin (200 μgml−1), and G418 (50 μgml− 1). For cell assays, cells in
the log phase of growth were replated in 24-well culture plates around 50–
60% conﬂuency, grown overnight and induced for the expression of
mHttex1-GFP for 8 h with 2 μM ponasterone A (Santa Cruz Biotechnologies).
To treat cells, different doses of polyQ40 seeds (1.0 pM–5 μM) or CSF (2%
ﬁnal concentration) sample were directly diluted from stock solution with
the same cell growth medium containing 2 μM ponasterone A for growth for
another 16 h. Equal volume of 1% fetal bovine serum diluted in 1×
phosphate-buffered saline was used as mock control.
Cell lysate seeding aggregation assay
Htt14A2.6 PC12 cells that were grown in medium containing 2 μM
ponasterone A for 8–10 h and induced expression of mHttex1-GFP but no
visible intracellular aggregates were harvested, rinsed, homogenized in cold
phosphate-buffered saline containing protease inhibitor cocktail, centrifuged
at 16 000 g for 30min at 4°C twice. Total protein concentrations of
supernatants were calibrated using the Sigma-Aldrich (St Louis, MO, USA)
total protein assay kit following vendor’s instruction. An aliquot of 100 μg
total protein of the supernatant, preformed oligomeric seeds or human or
BACHD CSF samples (2.5 μl) were mixed together to make a ﬁnal volume of
25 μl in an Eppendorf tube for incubation at RT in dark for 16 h. Aggregates
formed in the cell-free assays were then measured by ﬁlter retardation assay.
Filter retardation assay
Filter retardation was performed according to published methods with
minor modiﬁcations14 (see Supplementary Materials).
Dot blot immunoassays
Dot blot immunoassays are described in the Supplementary Materials.
Cryo-FLM and cryo-ET
Cryo-FLM and cryo-ET of polyQ40 seeded aggregates are described in the
Supplementary Materials.
Total internal reﬂection microscopy
Total internal reﬂection microscopy of polyQ40 or Aβ seeded aggregation
methods are described in the Supplementary Materials.
SDS-AGE gel electrophoresis
The gel analysis of oligomer-mediated seeding in the cell-free seeding
aggregation assay was carried out as previously described.15,16
Statistical analysis
Mixed model regression analyses17 (SAS Proc Mixed, v9.2) examined the
effects of condition (for example, 0–5000 nM), time (for example, 8, 16
and 24 h), and the condition × time interaction on percent aggregation or
amount of accumulation using a within-condition repeated measure-
ment factor. Covariances among the repeated measurement factors
were modeled with the unstructured-compound symmetry (un@cs)
covariance matrix and denominator degrees of freedom were estimated
using the Kenward–Roger method.18 The normality of the distribution could
not be determined with our sample size, therefore we also performed
nonparametric Friedman’s χ2-tests for repeated measures for which the
equal variance and normality assumptions of parametric tests are not
applicable. The nonparametric tests produced similar results (Supplementary
Table S5). We report the analysis of variance results given that the variables
are continuous and the reported means are considered more relevant and
interpretable to the ﬁeld than rank order values.
RESULTS
Mutant HTT aggregation can be selectively seeded by polyQ
oligomers
Exogenous applications of preformed oligomers have been shown
to induce protein aggregation in vitro and in vivo for several
proteins involved in neurodegeneration.19–21 In the case of
polyglutamine repeats, nucleation and seeding of aggregation
for polyglutamine repeats appears to be sequence speciﬁc.10 We
used an inducible Htt14A2.6 cell model that has previously been
used to assay agents that modulate formation of mHTT
aggregates12,16 as an assay system to evaluate whether exogen-
ous application of preformed oligomers could enhance aggrega-
tion of intracellular mHTT.12,16 This cell inducibly expresses a
fragment of mHTT (truncated exon 1) epitope tagged with
enhanced green ﬂuorescence protein (mHttex1-GFP) in the
presence of ponasterone A. We used synthetic polyQ (KKQ30KK
and KKQ40KK) oligomers as seeds to induce mHTT aggregation in
Htt14A2.6 cells. The assay was optimized to establish a limiting
concentration of ponasterone A such that aggregation was
minimal and any enhancement could be quantiﬁed. Oligomer
concentration and time course of aggregation seeding post
ponasterone A induction were also optimized. The percentage of
cells with visible GFP-tagged aggregates under ﬂuorescence and
differential interference contrast microscopy was correlated to the
concentration of KKQ40KK (polyQ40) seeds (10 nM–5 μM) and the
incubation time (8–24 h; Figure 1a). In control experiments, cells
without added polyQ40 show basal levels of aggregation
(Figure 1b). We established a second assay that could detect a
broader range of aggregated species using cell lysates (super-
natants) prepared from induced Htt14A2.6 cells (Figure 2a).
Notably, this assay provided greater sensitivity in detecting
seeding by polyQ than the cell-based assay to monitor visible
aggregates (Figure 2b). A control cell lysate experiment with
polyQ30 displays no enhanced aggregation (Supplementary
Figure S1).
To probe for evidence of a direct interaction of the seeds with
the induced aggregates and a potential mechanism for protein
propagation, we used a correlative study of cryo-FLM and cryo-ET.
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Cryo-FLM identiﬁed a range of aggregates of variable sizes and
morphologies (Figures 2c and d). The mixed colors of ﬂuorescence
conﬁrmed that they are formed by the Cy3-labeled polyQ40 seeds
and the inducibly expressed mHttex1-GFP. Cryo-ET of the same
polyQ40 seeded aggregates as identiﬁed in Cryo-FLM revealed a
range of aggregation species, including small oligomers, short and
long ﬁbrils and bundles of ﬁbril assemblies (Figures 2c and d;
Supplementary Movie S1).22,23 Similar results have been observed
in 14 tomograms from the corresponding cell lysate samples.
These seeded aggregates are much more diverse and larger than
those used for the seeding (Supplementary Figure S2b). In
addition to the induced aggregation detected using ﬁlter blots
and correlative cryo-FLM and cryo-ET imaging, newly formed
aggregation of mHttex1 seeded by polyQ40 oligomers was also
conﬁrmed using agarose gel electrophoresis (AGE gels) followed
by western blotting using a GFP-speciﬁc antibody (Supplementary
Figure S1) as described previously.15
To test whether the seeding of aggregation is template speciﬁc
for mHTT using the CBA seeding assays, Htt14A2.6 cells were
treated with 0.5 μM of Aβ1–40 and Aβ1–42 (Alzheimer’s disease
associated), and α-synuclein and A53T α-synuclein (Parkinson’s
disease associated) oligomers in the same manner as polyQ40
seeds. No signiﬁcant enhancement of intracellular mHttex1-GFP
aggregates was detected (Figure 3). Consistent results were
obtained from ﬁlter retardation-GFP immunoblotting following
the cell-free aggregation assay; no notable changes in mHttex1
aggregation were found in the cell lysates seeded with up to 5 μM
of Aβ1–40, Aβ1–42, α-synuclein or A53T α-synuclein oligomers,
using a 50-fold concentration increase over polyQ40 seeds
(Figures 3a and b). These observations were further corroborated
by the total internal reﬂection microscopy imaging results
(Supplementary Figure S3). In contrast to the polyQ40 oligomers
that were mostly linked with mHttex1-GFP aggregates from total
internal reﬂection microscopy imaging, few labeled Aβ1–42
oligomers overlapped with GFP ﬂuorescence from the mHttex1-
GFP aggregates (Supplementary Figure S3). In addition, Alexa
Flour 647-conjugated polyQ40 co-aggregated with mHTT aggre-
gates but not Aβ aggregates as determined by ﬂuorescence
correlation spectroscopy (data not shown), further supporting
template speciﬁcity.
Autopsy HD CSF ‘seeds‘ aggregation
Given that media or lysates from induced Htt14A2.6 cells is also
sufﬁcient to seed aggregation when transferred to new naïve cell
cultures (data not shown), we next determined whether the
property of seeding could be extended to human HD CSF. As a
ﬁrst step, immunoreactivity of mHTT was evaluated in postmor-
tem HD CSF samples (Supplementary Table S1) by spotting on
ﬁlter blots and probing with HTT speciﬁc antibodies. HTT was
detected in both HD and control CSF samples using a pan-HTT
antibody raised against the ﬁrst 17 amino-acid residues at the N
terminus of HTT (N17 antibody, Sigma-Aldrich). Importantly, an
antibody speciﬁc for expanded repeat HTT (MAB1574, EMD
Millipore) was immunoreactive only in HD samples (Figure 4a;
Supplementary Table S1), providing evidence that mHTT is indeed
present in HD patient CSF and could provide a template for
seeding. To next assess whether mHTT in HD CSF could seed
aggregation, 10 μl of HD or control CSF samples was added into
Htt14A2.6 cell culture medium (990 μl) and incubated for 16 and
24 h. Figure 4b depicts the raw percentage of cells containing
visible aggregates following CSF seeding (left panel) and the
relative increase in CSF seeding activity over mock control (no
CSF). In each case (n= 6 experiments), postmortem HD CSF
samples signiﬁcantly enhanced the percentage of cells with
aggregates compared with non-HD control CSF.
Consistent with the hypothesis that seeding is a mHTT-
dependent process, the aggregation seeding potency of CSF
from HD subjects was decreased when expanded polyQ-linked
mHTT fragments were immunodepleted using expanded polyQ-
speciﬁc antibody (MAB1574, Figure 4c). Seeding was dose
dependent as serial dilutions of HD CSF produced a corresponding
decrease in mHTT (Figure 4d), consistent with seeding being
dependent on the presence of mHTT. Aggregation by HD CSF was
also conﬁrmed using the cell-free lysate assay (Figure 4e). Levels of
insoluble mHttex1-GFP aggregates were also measured by ﬁlter
retardation-GFP immunoblotting (gel under the histogram of
Figures 4d and e) and showed a tight correspondence to the
seeding propensity.
CSF from BACHD rat distinguishes HD from controls
Autopsy CSF may contain substances related to postmortem
changes that are not present in CSF from living subjects. To
Figure 1. Enhanced formation of mHTT aggregates in inducible Htt14A2.6 cells by preformed polyQ40 (KKQ40KK) oligomeric seeds.
(a) Increased percentage of cells with mHTT aggregates (n= 6) with GFP tags following oligomeric polyQ seeding at 8, 16 and 24 h post
seeding. Error bars, s.e.m.; concentration: [F(6,42.4)= 53.91, Po0.0001]; time: [F(2,89.7)= 223.76, Po0.0001]; interaction: [F(12,52.6)= 2.69,
P= 0.0067]. (b) Microscopic images of Htt14A2.6 cells expressing GFP-tagged mHTT seeded with preformed polyQ40 oligomeric seeds at 16 h
post seeding. Bars indicate s.e.m. Each experiment had three to nine repeats. DIC, differential interference contrast. GFP, green ﬂuorescent
protein; mHTT, mutant huntingtin protein.
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Figure 2. Enhanced formation of mHTT aggregates in cell-free lysates derived from Htt14A2.6 cells by oligomeric polyQ seeds. (a) Schematic of
mHTT aggregation assay using ponasterone A-induced Htt14A2.6-derived whole-cell lysates (supernatants). (b) Dose-dependent
quantiﬁcation of mHTT aggregation from derived cell-free lysates on ﬁlter trap assay following oligomeric polyQ seeding. The y axis is the
number of fold increases over the vehicle control. Concentration: [F(8, 3.92)= 6.33, P= 0.048]. (c) Correlative cryo-FLM and cryo-ET of cell lysate
containing polyQ40 seeded mHttex1-GFP aggregates on electron microscope grids. Cryo-FLM identiﬁed a star-shaped aggregate that consists
of oligomer seeds (red) and mHttex1-GFP (green). Black dashed box showed the area where an electron microscope (EM) image (at
magniﬁcation of 4k) was taken (Black square is ice contamination adsorbed to the grid during transfer from light microscope to electron
microscope). This image was correlated to the cryo-FLM image to conﬁrm the aggregate’s identity. Yellow dashed box enclosed the region
where the tomographic tilt series shown in d was collected. (d) Section and three-dimensional annotated view of polyQ40 seeded mHttex1-
GFP aggregates in the cell lysate reveal the short mHTT ﬁbril (yellow), long ﬁbril and bundle aggregate structures (magenta), as well as cellular
vesicles (blue) from the lysates. Bars indicate s.e.m. Each experiment had three to nine repeats. Cryo-ET, cryo-electron tomography; cryo-FLM,
cryogenic-ﬂuorescent light microscopy; mHTT, mutant huntingtin protein.
Figure 3. PolyQ-related template-speciﬁc seeding for mHTT aggregation in inducible Htt14A2.6 cells and derived cell-free lysates. (a)
Percentage of cells with mHTT aggregates following oligomeric 0.1 μM polyQ40 and 0.5 μM of Aβ1–40 or Aβ1–42 seeding; seed condition: [F
(3,15.8)= 88.95, Po0.0001]; incubation time: [F(1,27)]= 7.79, P= 0.0095; interaction: [F(3,15.8)= 0.21, P=NS]. (b) Amount of mHTT
aggregation on ﬁlter trap assay following oligomeric 0.1 μM polyQ40 seeding and 5.0 μM of Aβ1–40, Aβ1–42, α-synuclein (SNCA), and A53T α-
synuclein in cell-free lysate assay. Seed condition: [F(5,4.3): 23.95, P= 0.003], *Po0.05, **Po0.001. Bars indicate s.e.m. Each experiment had
three to nine repeats. mHTT, mutant huntingtin protein; NS, not signiﬁcant.
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remove potential postmortem confounds, CSF was obtained from
BACHD rats that express a full-length human mHTT transgene at
17 months, when rats are symptomatic.24 CSF from ﬁve BACHD
and ﬁve wild-type rats was assayed (Figure 5a; Supplementary
Table S2). Each HD sample was clearly distinguished from controls.
Control rat CSF did not enhance aggregation above a mock
control, whereas BACHD CSF samples enhanced aggregation
similar to results observed for polyQ40 oligomer seeds.
CSF from living HD subjects ‘seeds‘ aggregation
On the basis of the autopsy and BACHD rat CSF results, we next
investigated whether aggregation could be seeded using a panel of
CSF samples (blinded) obtained from living PREDICT-HD (Neuro-
biological Predictors of Huntington’s Disease)25 subjects (diagnosed
with HD (n=2), expansion-gene-positive subjects without manifest
clinical symptoms (n=7) and healthy control subjects (n=2);
Figure 5b; Supplementary Table S3). The ﬁgure depicts measure-
ments for PREDICT living subjects as well as postmortem HD and
control subjects. The results for living and postmortem subjects are
consistent. HD subjects diagnosed by traditional clinical criteria
(that is, presence of movement disorder) were distinguished
without overlap from the control subjects by the percentage of
cells with aggregates and the amount of aggregates in the cell-free
lysate assay (Figures 5b and d). Seeding measures from expansion-
gene-positive subjects without clinical symptoms revealed a range
of seeding values between HD subjects and control values in this
relatively small cohort. This range could reﬂect time to conversion,
that is, onset of HD symptoms; however, this assessment will
require an additional study. We evaluated the ability of the assays
Figure 4. Postmortem CSF seeding enhancement of mHTT aggregation in inducible Htt14A2.6 cells and derived cell-free lysates. (a) Dot blots
detect amount of N-terminal (N17) in both autopsy HD and control CSF samples but expanded polyQ (Q436) only in HD CSF. (b) Normalized
percentage of cells with mHTT aggregates following seeding with CSF from autopsy HD and healthy control subjects (Ctl). Diagnosis:
[F(1,87.6)= 120.41, Po0.0001]; incubation time: [F(1,75)= 17.16, Po0.0001]; interaction: [F(1,75)= 36.35, Po0.0001]. See Figure 5b for
individual values. (c) Percentage of cells with mHTT aggregates following seeding with CSF from an autopsy HD subject (HD#134) that has
been depleted by polyQ expansion-speciﬁc antibodies at dilutions of 1/20, 1/100 and 1/500. Antibody dilution: F(3,7.29)= 45.8, Po0.0001. (d)
Amount of mHTT aggregates formed in 14A2.6 cell-free lysates seeded with HD CSF of Subject HD#134 at varying dilutions (that is, ﬁnal CSF
concentration= 10% in the cell-free lysate standard assay, 2% in ‘1/5‘ and 0.4% in ‘1/25‘ dilutions). (e) Amount of aggregate protein with GFP
tag in same subjects in cell-free assay. Diagnosis: [F(1,14.7)= 50.79, Po0.0001]. PolyQ: 0.1 μM polyQ40. Bars indicate s.e.m. Each experiment
had three to nine repeats. CSF, cerebrospinal ﬂuid; GFP, green ﬂuorescent protein; HD, Huntington’s disease; mHTT, mutant huntingtin protein.
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to distinguish clinical stage. The mean percentage of cells with
enhanced aggregation in the PREDICT-HD sample was signiﬁcantly
correlated with motor scores (total motor score; r= 0.79; P=0.01)
and cognitive dysfunction (Symbol digit modalities test; r= − 0.71,
P=0.03), but not with putamen volume (r= − 0.48; P=0.19). The
correlation between percent aggregation and CAG-Age Product
(CAP) score indexing disease burden26 was 0.54; for CAG (number
of repeats) alone it was 0.34. The CAP score is a better predictor of
clinical onset than the CAG expansion repeat as it takes into
consideration subject age, and age is a signiﬁcant predictor of
symptom onset. The correlation between CAP score and total
motor score is 0.67, Po0.05, and CAP score and symbol digit
modalities test is − 0.72, Po0.03. The corresponding correlations
with the CBA cell-free lysate assay were smaller and did not reach
statistical signiﬁcance, although they did distinguish HD from non-
HD controls (Figure 5c). The correlation between the two CBA
measures, mean percentage of cells with aggregates and cell-free
fold increases, was 0.58. If conﬁrmed in longitudinal studies, these
data suggest that a combination of the two CBA assay measure-
ment approaches could ultimately provide unique beneﬁt in the
development of molecular biomarker assays for screening efﬁcacy
of drugs that reduce mHTT CSF load in HD subjects and possibly in
tracking disease stage. These possibilities will be explicitly tested in
future studies by testing additional CSF samples and optimized
methods of quantiﬁcation and assessments of therapies such as
mHTT lowering treatments.
To evaluate the speciﬁcity of seeding in human samples, CSF
from 10 subjects with mixed dementia was also tested in the cell-
free lysate assay. Similar to the oligomer seeding studies above in
which Aβ did not show seeding, none of the mixed dementia CSF
showed enhancement of newly formed mHTT aggregates (Figures
5c and d), supporting template dependence and speciﬁcity for HD
pathogenesis. Supplementary Table S4 provides evidence of
nonseeding for non-HD subjects with a wide range of Aβ42, tau
and p-tau values.
DISCUSSION
There is an urgent need to develop effective treatments for HD.
Reliable molecular biomarkers of disease in patient bioﬂuids has
Figure 5. Enhanced mHTT aggregation (relative to mock) in blinded CSF samples from living PREDICT subjects. (a) Amount of mHTT
aggregates from cell-free lysates seeded with CSF from BACHD transgenic rats (BAC) and wild-type rats (WT). BACHD vs WT:
[F(1,15.6)= 117.74, Po0.0001]. (b) Relative (to mock control) levels of cells with mHTT aggregates (bars) with GFP tags following 24 h
seeding with CSF from blinded PREDICT living samples (bracketed), and autopsy HD and controls (HD#, Ctl#; converted data from Figure 4b),
reordered for clarity. HD subjects with clinical motor symptoms in red, CAG expansion-gene-positive subjects without clinical symptoms in
yellow, healthy controls in blue. Autopsy HD subjects in light red, and autopsy controls in light blue. Group (HD, CAG expansion-gene-positive,
and controls): [F(2,19.6)= 37.82, Po0.0001]. HD4CAG expansion-gene-positive4Controls, all Pso0.001. (c) Amount of aggregate protein
with GFP tags following seeding with CSF from blinded PREDICT samples, with autopsy HD (HD#) and polyQ control subjects (upper) and with
CSF from 10 subjects with mixed dementia (AD, Lewy body, and frontal temporal; lower; see Supplementry Figure S5A for original gels). (d)
Relative amount of mHTT in cell-free lysate assay following seeding with CSF from grouped PREDICT-HD subjects with clinical symptoms (red),
expansion-gene-positive subjects without clinical symptoms (yellow), and controls (blue; autopsy and PREDICT controls (CTL); and non-HD
dementia controls (data from c)). **Po0.001, ***Po0.0001. Bars indicate s.e.m. Each experiment had three to nine repeats. CSF, cerebrospinal
ﬂuid; GFP, green ﬂuorescent protein; HD, Huntington’s disease; mHTT, mutant huntingtin protein.
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been elusive for the evaluation of potential therapeutics; however,
there are emerging possibilities using HD patient CSF.27 Here we
provide evidence that a mHTT-speciﬁc and disease pathogenic
property exists in HD CSF that can be identiﬁed using a surrogate
assay (that is, CBA seeding) to measure an increased propensity to
seed the number of cells having visible aggregates and the
amount of aggregation in cell lysates. Importantly, seeding is
template speciﬁc for mHTT. This CBA seeding activity may be
highly relevant to pathogenesis of neurodegenerative diseases
based on growing evidence indicating that oligomers of
aggregating peptides or proteins such as Aβ, α-synuclein and
tau are transmissible between cells,28–30 and can thereby spread
and enhance both homologous and heterologous aggregation
through nucleation seeding in a cell-to-cell protein propagation
or ‘prion-like‘ manner.28–31 α-Synuclein and Aβ are detected in
CSF and measurements of their abundance or ratio are being
considered as sensitive biomarkers for Parkinson’s and Alzheimer’s
diseases, respectively.32–35 More recent work in HD model systems
supports cell-to-cell transfer of mHTT aggregation. For instance,
mHTT exon 1 protein fused to nonﬂuorescent halves of a
ﬂuorescent protein, which requires dimerization-mediated bio-
molecular ﬂuorescence complementation to be visualized, pro-
vided direct evidence of mHTT transfer between cells.36 Trans-
neuronal propagation of mHTT was also observed using in vitro
and in vivo approaches, demonstrating the movement of mHTT
from cortical neurons to striatal medium spiny neurons37 and from
HD tissue into non-HD fetal neural allografts,38 supporting a direct
involvement or consequence of pathogenesis. Here we report that
mHTT can be detected in HD CSF using expanded repeat-speciﬁc
antibodies. This is consistent with a new study showing that
soluble and nomomeric HTT can be quantitatively detected in CSF
by an ultrasensitive immunoassay.27 Our study demonstrates that
exogenous polyQ oligomers and CSF containing mHTT can seed
aggregation in our PC12 cell-based models. This supports the idea
that a prion-like protein transmission may be involved. This
mechanism will be further clariﬁed by evaluating the kinetics of
aggregation in future studies. The presence of the protein is
required for seeding to occur, potentially supporting a direct
relationship between seeding and pathology in HD. Our data is
consistent with the observations in Alzheimer’s and Parkinson’s
disease that seeding with native protein is much more efﬁcient
than synthetic seeds,39 reﬂecting the likelihood that additional
properties present in patient-derived CSF beyond the mHTT
protein can also be captured as a modulator of cell-to-cell
propagation, including the presence of neuroinﬂammatory
cytokines. Indeed, we ﬁnd that seeding of aggregation in
inducible Htt14A2.6 cells can be further enhanced by cytokines
such as interleukin-1β (unpublished results). Given literature
demonstrating that aberrant immune activation is observed in
HD patient CSF even prior to onset of disease symptoms,40 our
ﬁnding that patient CSF has aggregation enhancing activity may
reﬂect multiple molecular characteristics of disease.
Our studies demonstrate that a signiﬁcant increase in newly
formed mHTT-containing aggregates was consistently found in
Htt14A2.6 cells and cell-free lysates seeded with HD CSF samples
but not with CSF from healthy controls without the HD expansion.
CSF from expansion-gene-positive subjects who have not yet
developed clinical motor symptoms revealed a range of seeding
results from HD to non-HD measures, raising the possibility that
CSF seeding might provide a measure of HD progression, that is,
will those with higher seeding levels be the ﬁrst to convert to
clinical HD? This possibility will be assessed in future studies with
longitudinal patient samples from individuals who have since
converted to disease. The range of ﬁndings are consistent with
that seen in clinical and imaging markers showing an insidious
increase in clinical symptoms in concert with the progressive loss
of regional brain volume.41
The CSF seeding results also suggest that treatments may be
effective by blocking the extracellular cell-to-cell transmission of
mHTT. This is consistent with the propagation of HD pathology
shown by Pecho-Vrieseling37 and Cicchetti,38 although the
identiﬁcation of mHTT aggregates exclusively within the extra-
cellular matrix of fetal allografts in the latter study may be a
consequence of alternative mechanisms involving the host
immune cells. The implications from these cross-sectional data
remain to be conﬁrmed in longitudinal studies of expansion-gene-
positive subjects as well as further longitudinal analysis from HD
models (for example, BACHD rat model).
Determining the temporal order and the slope of change of
biomarkers in the progression of gene-expansion-positive subjects
to HD is important for monitoring progression and designing
clinical trials that incorporate surrogate markers. The Dominantly
Inherited Alzheimer’s Network (DIAN) study data provide a
relevant example of having the optimal biomarker at various
stages of disease. On the basis of cross-sectional data, Bateman
et al.42 proposed a temporal order in which biomarkers become
abnormal before the Alzheimer’s disease onset. The most sensitive
for early detection (15 years before symptoms) are cerebral
deposition of ﬁbrillar amyloid on PET and increased levels of CSF
tau protein. However, once clinical dementia onset begins, ﬂuoro-
deoxy-glucose PET, hippocampal volume and CSF tau may be most
reﬂective of clinical progression. The choice of biomarkers depends
on the stage of illness and the therapeutic target, for example, anti-
amyloid or anti-tau. The DIAN study results are applicable to HD
biomarkers such as assays that can quantitatively monitor the
seeding property identiﬁed here in HD CSF. The lack of any overlap
in the CBA measures between HD (n=7) and non-HD control
(n=17) subjects is noteworthy. Individualized treatment depends
on prediction for the individual, not a difference in group means.
Taken together, these data show that an HD-speciﬁc property
exists in patient CSF that can be monitored in relatively simple cell-
based assays. These ﬁnding suggest that this CSF-enhanced aggre-
gation property could potentially form the basis for monitoring the
stage and course of HD as well as serve as a molecular biomarker for
therapeutic interventions that alter levels of mHTT in CSF.
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